ADAP (Adaptimmune) שולי הרווח הגולמי

סמל תאגידי ולוגו של Adaptimmune Therapeutics (ADAP)

Adaptimmune relies on SPEAR T-cell, creating a closed environment for the genetic modification of lymphocytes. The development of this biopharmaceutical company depends on scientific discoveries rather than market cycles. The gross margin reflects the profit share after deducting production costs, where 0.00 becomes the new value of the indicator. Efficiency is supported by seamless express logistics of biomaterials between clinics and laboratories.

ADAP - שולי רווח גולמי adaptimmune.com בטווח 04.07.2022 - 15.11.2025

פילוחי מדדים מקיפים ואנליטיקה עבור adaptimmune.com (ADAP)

הערכת שווי פונדמנטלית:Adaptimmune (ADAP)
מוצרים מיוצרים של Adaptimmune

Gross margin measures production efficiency by determining the portion of revenue remaining after direct product creation costs. Analyzing the ratio of gross profit to revenue allows for an assessment of the operational resilience of Adaptimmune, which, amid geopolitical restrictions and disruptions in cell material logistics, may exhibit increased sensitivity to the cost of cross-border research and regulatory expenses.